Dr. Gabriel Oliveira Sawakuchi's lab focuses on combining innovative radiation therapy techniques with pharmacologic strategies to enhance the immune response against cancer. The lab investigates how high-energy alpha particles and inhibitors of DNA repair can work together to activate the immune system, particularly in difficult-to-treat solid tumors. This research seeks to improve cancer treatment outcomes and develop new therapeutic approaches for patients with advanced cancers.

Dr. Bogdan A Czerniak's lab focuses on understanding bladder cancer, a common and deadly disease. The research aims to identify how bladder cancer develops and evolves, particularly looking at the cellular changes that contribute to its severity and resistance to treatment. By characterizing the molecular mechanisms involved, the lab aims to develop new therapies to improve early detection and treatment outcomes for bladder cancer patients.

Dr. Li Ma's research lab focuses on improving the treatment of bone metastasis in cancer patients, particularly in breast cancer. They investigate a protein called ACBP, which influences how cancer cells metabolize fats and survive in bone tissue. By understanding ACBP's role in tumor biology, the lab aims to develop new therapeutic strategies that target bone metastasis more effectively than current treatments, which mainly alleviate symptoms but do not address the underlying cancer.

Dr. Susan Bullman's lab at the University of Texas MD Anderson Cancer Center focuses on understanding the interactions between specific bacteria, particularly Fusobacterium nucleatum, and colorectal cancer. The team investigates how these bacteria alter the tumor environment and influence cancer progression and patient outcomes. Their research aims to uncover novel therapeutic targets that could improve cancer treatment and prevention.

Dr. Jae-Il Park's lab focuses on understanding the biology and treatment of aggressive cancers, specifically small cell lung cancer (SCLC) and esophageal squamous cell carcinoma (ESCC). The lab employs cutting-edge model systems, including genetically engineered mouse models and organoids, to investigate how tumor suppressor genes and immune landscape remodeling affect cancer initiation and progression. By uncovering the molecular mechanisms behind these cancers, the lab aims to identify novel therapeutic targets and improve patient outcomes.

Dr. Ronald Anthony Depinho's lab at the University of Texas MD Anderson Cancer Center focuses on understanding how specific gene deletions in cancer cells can create unique vulnerabilities. By identifying these weak spots, the lab aims to develop precision cancer therapies that target only cancer cells while sparing normal ones. They utilize advanced techniques such as CRISPR to explore these genetic interactions and aim to improve treatment outcomes for cancer patients.

Dr. Lilie Leming Lin's research focuses on understanding how biological aging affects immunity and cancer outcomes in women living with HIV, particularly those with cervical cancer. Her lab investigates the differences in biological aging between HIV-positive and HIV-negative cervical cancer patients and how this aging impacts their responses to standard cancer treatments. The goal is to identify biomarkers of aging that could help personalize treatment approaches for these populations.

Dr. Rebecca Maureen Howell's lab focuses on improving the health outcomes of childhood cancer survivors, particularly in reducing the risk of cardiovascular disease. The lab is working on creating advanced models to predict cardiovascular risks based on specific doses of radiation received during cancer treatment. By personalizing risk assessments, they aim to improve both current treatment planning and future healthcare strategies for survivors.

Dr. Xiaodong Cheng's lab focuses on understanding how modifications to DNA and histones can affect gene expression. By studying the molecular mechanisms behind these epigenetic changes, the lab aims to uncover how transcription factors interact with DNA and how these processes can influence health and disease. This research is particularly relevant for developing new therapeutic strategies targeting gene regulation.

Dr. Liang Li's lab focuses on understanding and treating diseases affecting the exocrine pancreas, particularly chronic pancreatitis and its serious complications, such as diabetes and pancreatic cancer. The lab works on collecting and analyzing clinical data to support the development of new therapies and biomarkers, which can enhance patient care and disease understanding. Collaborating with a network of clinical researchers, they aim to improve patient outcomes through comprehensive studies.

David Fuentes' lab specializes in developing sophisticated mathematical models to understand and optimize a new therapeutic approach for treating liver cancer. The team focuses on how fluids behave and transfer heat within biological tissues, especially during a treatment called thermoembolization. Their interdisciplinary approach combines knowledge from areas like imaging, biochemistry, and interventional radiology to enhance cancer treatment protocols.

Dr. Jlenia Guarnerio's lab focuses on improving treatments for soft-tissue sarcomas, a type of cancer with low survival rates. The research investigates how circular RNAs can affect the immune response to a specific cancer drug called Abemaciclib. By understanding these interactions, the lab aims to enhance the drug's effectiveness and improve outcomes for patients.

Dr. Clifton David Fuller leads research focused on improving the care and quality of life for patients with head and neck cancers. His lab uses advanced imaging techniques and artificial intelligence to better detect and prevent lymphedema and fibrosis—complications that many survivors experience after treatment. By enhancing CT scans and treatment planning, the goal is to help patients face fewer long-term health issues after cancer treatment.

Dr. Laura Beretta's lab focuses on improving early detection methods for hepatocellular carcinoma (HCC), a deadly form of liver cancer. By studying patients with cirrhosis, the lab aims to discover effective blood tests and modern imaging techniques to identify HCC earlier, which can greatly enhance treatment options and survival rates. Their work combines innovative biomarker analysis and advanced imaging technologies, including artificial intelligence, to better understand cancer risk and progression.

Dr. Wen Jiang's lab focuses on innovative cancer immunotherapy techniques, particularly using macrophages to target solid tumors like breast cancer and glioblastoma. The research aims to engineer macrophages in vivo to enhance their ability to fight tumors by using mRNA-loaded exosomes, which may simplify current cell therapy methods. This work is significant as it seeks to overcome challenges in traditional CAR T cell therapies, making cancer treatments more effective.

Dr. Raghu Kalluri's lab focuses on understanding exosomes, tiny particles that cells release into the bloodstream, and their roles in cancer, particularly pancreatic cancer. They investigate how these exosomes contribute to cancer progression and explore innovative ways to use engineered exosomes as potential therapies. The lab aims to uncover the mysteries of exosome biology and harness their properties for improving cancer diagnosis and treatment.

Dr. Xi Chen's lab focuses on understanding how mutant KRAS, a common gene mutation in several cancers, influences tumor growth and response to treatment. They are particularly interested in how cancer cells adapt to therapies and develop resistance, with a specific focus on a molecular process called proteostasis. By targeting these mechanisms, the lab aims to improve the effectiveness of existing treatments for lung, pancreatic, and colorectal cancers, potentially leading to better outcomes for patients.

Dr. Lawrence Kwong's lab studies cholangiocarcinoma, a serious form of bile duct cancer. The lab focuses on understanding how cancer cells change their identities, a process known as lineage plasticity, which can affect how aggressive the cancer is and how well it responds to treatment. By exploring the genetic and molecular underpinnings of this plasticity, the lab aims to identify new biomarkers and treatment strategies to improve patient outcomes.

Dr. Chun Li's lab focuses on developing new therapies for hepatocellular carcinoma (HCC), a type of liver cancer that is becoming increasingly common. The lab is exploring the use of polymeric micelles that can deliver dual drug therapies effectively to target cancer stem cells and other tumor cells. This innovative approach aims to improve treatment outcomes and ultimately provide better survival rates for HCC patients.

Dr. Zhongxing Liao's lab at the University of Texas MD Anderson Cancer Center focuses on improving the safety and effectiveness of radiation therapy for lung cancer patients. Their primary goal is to minimize the risk of heart damage caused by radiation treatments by developing a personalized risk assessment model that considers individual patient factors. By analyzing pre-existing cardiovascular risks, they aim to guide physicians in choosing the most suitable treatment plans for non-small cell lung cancer (NSCLC) patients, ultimately leading to better patient outcomes and quality of life.